Inactive Instrument
Company Vical Incorporated Nasdaq
Stocks
US9256022032
Biotechnology & Medical Research
Business description: Vical Incorporated

Sales by Activity: Vical Incorporated
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
Pharmaceuticals | 7.92M | 1.82M | 404K | 6.94M | 8.01M |
Geographical breakdown of sales: Vical Incorporated
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
United States | 7.92M | 1.82M | 404K | 6.94M | 8.01M |
Executive Committee: Vical Incorporated
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 74 | - |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 2015-12-31 |
Aaron Fox-Collis
DFI | Director of Finance/CFO | - | 2022-05-31 |
Aron Aizenstat
PRN | Corporate Officer/Principal | - | - |
Sue Fattor
HRO | Human Resources Officer | - | - |
Company details: Vical Incorporated

Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.49% | -3.76% | +50.31% | +62.10% | 63.66B | ||
| -0.63% | -2.91% | +6.20% | +89.22% | 58.56B | ||
| -2.37% | -2.22% | +22.87% | +82.31% | 54.19B | ||
| -2.19% | -6.15% | +11.92% | +108.08% | 44.66B | ||
| -1.89% | -7.28% | +13.22% | +19.74% | 40.51B | ||
| -0.93% | -0.47% | +19.73% | +43.75% | 36.27B | ||
| +1.11% | -6.44% | +130.68% | +641.83% | 34.89B | ||
| -0.80% | +0.61% | +77.26% | +56.26% | 32.26B | ||
| -2.17% | +16.65% | -29.21% | +474.05% | 31.01B | ||
| Average | -1.37% | -1.22% | +33.67% | +175.26% | 44B | |
| Weighted average by Cap. | -1.48% | -1.85% | +32.16% | +150.90% |
















